CN117233396A - Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus - Google Patents

Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus Download PDF

Info

Publication number
CN117233396A
CN117233396A CN202210241035.9A CN202210241035A CN117233396A CN 117233396 A CN117233396 A CN 117233396A CN 202210241035 A CN202210241035 A CN 202210241035A CN 117233396 A CN117233396 A CN 117233396A
Authority
CN
China
Prior art keywords
pro
leu
extracellular matrix
matrix protein
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210241035.9A
Other languages
Chinese (zh)
Inventor
张曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202210241035.9A priority Critical patent/CN117233396A/en
Publication of CN117233396A publication Critical patent/CN117233396A/en
Pending legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

The invention provides application of urine extracellular matrix protein 1 (Extracellular matrix protein 1) and polypeptide fragments thereof, in particular application of the urine extracellular matrix protein 1 and polypeptide fragments thereof in preparation of diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like of systemic lupus erythematosus (Systemic lupus erythematosus, SLE). SLE is a diffuse connective tissue disease mediated by autoimmunity and highlighted by immune inflammation, most of which appear as hidden diseases and often involve multiple systems of the body. The invention proves that the expression of the urine extracellular matrix protein 1 and the polypeptide fragment thereof in SLE active patients is reduced through researches. Detection can be applied for various purposes of SLE patients. The invention plays the advantages of noninvasive acquisition of urine samples, large-scale repeated sampling and convenient preservation, and utilizes the urine samples to detect the extracellular matrix protein 1 and the polypeptide fragments thereof.

Description

Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus
Technical Field
The invention relates to a new application of urine extracellular matrix protein 1 and a polypeptide fragment thereof, in particular to an application of urine extracellular matrix protein 1 and a polypeptide fragment thereof in SLE diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Background
Systemic lupus erythematosus (Systemic lupus erythematosus, SLE) is an autoimmune connective tissue disease that can involve multiple organs throughout the body, well developed in women of childbearing age. According to epidemiological statistical studies, SLE prevalence in China is 70/10 ten thousand, and women are up to 113/10 ten thousand. The cause of the disease is not clear, SLE is frequently a hidden onset disease, clinical manifestations are complex and various, and red spots distributed in the nose bridge and cheeks in butterfly form are changes of SLE characteristics. Skin lesions of SLE also include light sensitivity, hair loss, hand and foot palmar and periungual erythema, discoid erythema, reynolds phenomenon, and the like. In addition, SLE often develops in multiple systems, especially those involving vital visceral systems such as lupus nephritis, neuropsychiatric lupus, pericardial effusion, blood and digestive system damage. It can be seen that the method is particularly important for timely diagnosis, effective disease monitoring and targeted treatment of the patient.
Extracellular matrix protein 1 (Extracellular matrix protein, ECM 1) is a secreted protein involved in biological processes such as cell proliferation, angiogenesis, embryogenesis, skin differentiation and tumor formation. The ECM1 gene is located in the epidermal differentiation complex (Epidermal differentiation complex, EDC) region adjacent to human chromosome 1q21, and contains 10 exons, which are closely related to the keratinocyte differentiation process. The extracellular matrix protein 1 content of SLE active patients in urine is reduced in the study.
Compared with the common clinical blood sample, the urine can be completely and noninvasively collected continuously in a large amount; without steady state regulation, more kinds and larger amplitude of changes can be accumulated, and many pathophysiological changes of the body may be manifested in urine. Protein polypeptides with relatively small molecular weights such as hormones and cytokines can be excreted into urine quickly after entering blood, and the probability of being detected in the urine is much higher than that in the blood; prior to urine collection, the possible proteolytic processing of urine is completed, so that urine proteins remain stable for a longer period of time. In order to relieve the pain of patients with SLE caused by repeated blood sampling, the experiment is expected to realize the diagnosis and disease monitoring of SLE patients with painless, convenient, quick and easily repeated urine detection through urine protein or polypeptide research on the basis of early-stage methodology, and lays a foundation for further research of urine polypeptide detection kits.
Disclosure of Invention
The invention aims to provide an application of urine extracellular matrix protein 1 and polypeptide fragments thereof in preparing SLE diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like
Preferably, the amino acid sequence of the urine extracellular matrix protein 1 comprises the amino acid sequence shown in SEQ ID NO.1 (MGTTARAALV LTYLAVASAA SEGGFTATGQ RQLRPEHFQE VGYAAPPSPP LSRSLPMDHP DSSQHGPPFE GQSQVQPPPS QEATPLQQEK LLPAQLPAEK EVGPPLPQEA VPLQKELPSL QHPNEQKEGT PAPFGDQSHP EPESWNAAQH CQQDRSQGGW GHRLDGFPPG RPSPDNLNQI CLPNRQHVVY GPWNLPQSSY SHLTRQGETL NFLEIGYSRC CHCRSHTNRL ECAKLVWEEA MSRFCEAEFS VKTRPHWCCT RQGEARFSCF QEEAPQPHYQ LRACPSHQPD ISSGLELPFP PGVPTLDNIK NICHLRRFRS VPRNLPATDP LQRELLALIQ LEREFQRCCR
QGNNHTCTWK AWEDTLDKYC DREYAVKTHH HLCCRHPPSP TRDECFARRA PYPNYDRDIL TIDIGRVTPN LMGHLCGNQR VLTKHKHIPG LIHNMTARCC DLPFPEQACC AEEEKLTFIN DLCGPRRNIW RDPALCCYLS PGDEQVNCFN INYLRNVALV SGDTENAKGQ GEQGSTGGTN ISSTSEPKEE), SEQ ID NO.2 (MGTTARAALV LTYLAVASAA SEGGFTATGQ RQLRPEHFQE VGYAAPPSPP LSRSLPMDHP DSSQHGPPFE GQSQVQPPPS QEATPLQQEK LLPAQLPAEK EVGPPLPQEA VPLQKELPSL QHPNEQKEGT PAPFGDQSHP EPESWNAAQH CQQDRSQGGW GHRLDGFPPG RPSPDNLNQI CLPNRQHVVY GPWNLPQSSY SHLTRQGETL NFLEIGYSRC CHCRSHTNRL ECAKLVWEDT LDKYCDREYA VKTHHHLCCR HPPSPTRDEC FARRAPYPNY DRDILTIDIG RVTPNLMGHL CGNQRVLTKH KHIPGLIHNM TARCCDLPFP EQACCAEEEK LTFINDLCGP RRNIWRDPAL CCYLSPGDEQ VNCFNINYLR NVALVSGDTE NAKGQGEQGS TGGTNISSTS EPKEE), SEQ ID NO.3 (MALPLRDRVK EATPLQQEKL LPAQLPAEKE VGPPLPQEAV PLQKELPSLQ HPNEQKEGTP APFGDQSHPE PESWNAAQHC QQDRSQGGWG HRLDGFPPGR PSPDNLNQIC LPNRQHVVYG PWNLPQSSYS HLTRQGETLN FLEIGYSRCC HCRSHTNRLE CAKLVVRLGS), SEQ ID NO.4 (MGTTARAALV LTYLAVASAA SEGGFTATGQ RQLRPEHFQE VGYAAPPSPP LSRSLPMDHP DSSQHGPPFE GQSGKEGRGP RPHSQPWLGE RVGCSHIPPS IVQPPPSQEA TPLQQEKLLP AQLPAEKEVG PPLPQEAVPL QKELPSLQHP NEQKEGTPAP FGDQSHPEPE SWNAAQHCQQ DRSQGGWGHR LDGFPPGRPS PDNLNQICLP NRQHVVYGPW NLPQSSYSHL TRQGETLNFL EIGYSRCCHC RSHTNRLECA KLVWEEAMSR FCEAEFSVKT RPHWCCTRQG EARFSCFQEE APQPHYQLRA CPSHQPDISS GLELPFPPGV PTLDNIKNIC HLRRFRSVPR NLPATDPLQR ELLALIQLER EFQRCCRQGN NHTCTWKAWE DTLDKYCDRE YAVKTHHHLC CRHPPSPTRD ECFARRAPYP NYDRDILTID IGRVTPNLMG HLCGNQRVLT KHKHIPGLIH NMTARCCDLP FPEQACCAEE EKLTFINDLC GPRRNIWRDP ALCCYLSPGD EQVNCFNINY LRNVALVSGD TENAKGQGEQ)
GSTGGTNISS TSEPKEE); or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO 1-4 and has the same function as the amino acid sequence shown in SEQ ID NO 1-4.
Preferably, the preparation is a detection kit for urine extracellular matrix protein 1 and polypeptide fragments thereof of SLE patients.
Preferably, the kit comprises one or more of an immunization method of antigen-antibody reaction and a kit thereof, such as an aptamer antibody or an antibody fragment capable of specifically binding to extracellular matrix protein 1 and a polypeptide fragment thereof.
Preferably, the detection method comprises a method of directly detecting mass spectrum of extracellular matrix protein 1 and polypeptide fragments thereof and the like and a related kit thereof.
Preferably, the detection method comprises methods such as related nucleic acid detection for directly detecting extracellular matrix protein 1 and polypeptide fragments thereof and related kits thereof.
Preferably, the kit further comprises a component selected from the group consisting of: solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, secondary antibody diluent, luminous reagent, washing liquid, color developing liquid and stop solution.
Preferably, the standard comprises an extracellular matrix protein 1 standard, a humanized tag antibody standard; preferably, the quality control product comprises: extracellular matrix protein 1 quality control and humanized tag antibody quality control; preferably, the solid support comprises: microparticles, microspheres, slides, test strips, plastic beads, liquid phase chips, microwell plates or affinity membranes, and other carriers of equivalent function.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose and has similar functions.
The inventors first collected urine samples from healthy persons, SLE active patients (aSLE) and stationary phase patients (sSLE), centrifuged at 4000r/min for 5min, and the supernatant was aspirated, and the protein concentration was measured by the Bradford method for SDS-PAGE enzymatic hydrolysis. Label-free mass spectrometry of urine samples was performed by an orbitrapF type mass spectrometer. The data obtained in mass spectrometry for SLE group and normal control group were quantitatively calculated. Screening the differential polypeptide by taking the difference of protein expression amount over 1.5 times and the P <0.05 as a reference standard through statistical test. Then the inventor identifies the differential polypeptide with statistical significance, and searches by using a database to obtain the differential protein extracellular matrix protein 1. The inventor uses Western Blot immunoblotting test and parallel reaction monitoring technology (PRM) to verify extracellular matrix protein 1 and the content thereof in urine of SLE patients and healthy people.
The research proves that the extracellular matrix protein 1 and the polypeptide fragment thereof are expressed in urine of SLE active patients, and have better consistency with clinical diagnosis. Therefore, the detection of the extracellular matrix protein 1 of urine and the polypeptide fragment thereof can be used for the auxiliary diagnosis or disease monitoring of SLE.
The invention plays the advantages of noninvasive acquisition of urine samples, large-scale repeated sampling and convenient preservation, and utilizes the urine samples to detect the extracellular matrix protein 1 and the polypeptide fragments thereof.
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments, as illustrated in the accompanying drawings.
Drawings
FIG. 1 is a graph showing the content of extracellular matrix protein 1 and polypeptide fragments thereof in SLE patients and healthy control groups.
FIG. 2 is a graph showing Western Blot immunoblotting test results of extracellular matrix protein 1 of urine and polypeptide fragments thereof in SLE patients and healthy control groups.
FIG. 3 is a quantitative view of urine extracellular matrix protein 1 and polypeptide fragments thereof in a PRM of a SLE patient and a healthy control group.
Detailed Description
Example 1Urine specimen collection and processing
SLE patients were selected as SLE group, and contemporaneous healthy physical examination persons were selected as normal control group. 30ml of fresh morning urine samples of each group of study subjects were collected after admission, and the urine in the morning catheters was collected by the disabled and placed in a dry, clean container. Centrifuging the collected urine specimen at 4000r/min for 5min, sucking the supernatant, subpackaging 2ml per tube, and storing in a refrigerator at-80 ℃.
Example 2Mass spectrometry and screening of urine polypeptides
Urine sample protein is extracted and the concentration of the extracted protein is determined. Mass spectrometry of urine samples was performed by orbitrapf type mass spectrometry. The data obtained in the mass spectrum of the experimental group and the normal control group are quantitatively calculated. The comparison between groups adopts t-test for differential analysis, and the differential expression protein is screened by taking the difference of protein expression amount over 1.5 times and the P <0.05 as a reference standard through statistical test.
Example 3Identification and analysis of differential Polypeptides
The database used is a uniprot_homo database, the generated mass spectrum original file is processed by MaxQuant software, and the retrieval parameter setting is shown in table 1.
Example 4Verification of urine extracellular matrix protein 1
The results of Label-free mass spectrometry show that extracellular matrix protein 1 is low-expressed in urine of SLE active patients, the content of the extracellular matrix protein 1 in urine of SLE patients and healthy control groups is shown in figure 1, the extracellular matrix protein 1 in urine of SLE patients and healthy people is detected by using Western Blot immunoblotting test, the results of which are shown in figure 2, and the extracellular matrix protein 1 in urine of SLE patients and healthy people is detected by using Parallel Reaction Monitoring (PRM), and the results of which are shown in figure 3. The results were confirmed to be consistent, with significant differences in extracellular matrix protein 1 expression between groups.
Although the invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention, and the invention is defined in the following claims.
Sequence listing
<110> Bowman
<120> application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus
<130> 22PECM1-CN
<140> 22PECM1-CN
<141> 2022-02-17
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 540
<212> PRT
<213> Human Urine
<400> 1
Met Gly Thr Thr Ala Arg Ala Ala Leu Val Leu Thr Tyr Leu Ala Val
1 5 10 15
Ala Ser Ala Ala Ser Glu Gly Gly Phe Thr Ala Thr Gly Gln Arg Gln
20 25 30
Leu Arg Pro Glu His Phe Gln Glu Val Gly Tyr Ala Ala Pro Pro Ser
35 40 45
Pro Pro Leu Ser Arg Ser Leu Pro Met Asp His Pro Asp Ser Ser Gln
50 55 60
His Gly Pro Pro Phe Glu Gly Gln Ser Gln Val Gln Pro Pro Pro Ser
65 70 75 80
Gln Glu Ala Thr Pro Leu Gln Gln Glu Lys Leu Leu Pro Ala Gln Leu
85 90 95
Pro Ala Glu Lys Glu Val Gly Pro Pro Leu Pro Gln Glu Ala Val Pro
100 105 110
Leu Gln Lys Glu Leu Pro Ser Leu Gln His Pro Asn Glu Gln Lys Glu
115 120 125
Gly Thr Pro Ala Pro Phe Gly Asp Gln Ser His Pro Glu Pro Glu Ser
130 135 140
Trp Asn Ala Ala Gln His Cys Gln Gln Asp Arg Ser Gln Gly Gly Trp
145 150 155 160
Gly His Arg Leu Asp Gly Phe Pro Pro Gly Arg Pro Ser Pro Asp Asn
165 170 175
Leu Asn Gln Ile Cys Leu Pro Asn Arg Gln His Val Val Tyr Gly Pro
180 185 190
Trp Asn Leu Pro Gln Ser Ser Tyr Ser His Leu Thr Arg Gln Gly Glu
195 200 205
Thr Leu Asn Phe Leu Glu Ile Gly Tyr Ser Arg Cys Cys His Cys Arg
210 215 220
Ser His Thr Asn Arg Leu Glu Cys Ala Lys Leu Val Trp Glu Glu Ala
225 230 235 240
Met Ser Arg Phe Cys Glu Ala Glu Phe Ser Val Lys Thr Arg Pro His
245 250 255
Trp Cys Cys Thr Arg Gln Gly Glu Ala Arg Phe Ser Cys Phe Gln Glu
260 265 270
Glu Ala Pro Gln Pro His Tyr Gln Leu Arg Ala Cys Pro Ser His Gln
275 280 285
Pro Asp Ile Ser Ser Gly Leu Glu Leu Pro Phe Pro Pro Gly Val Pro
290 295 300
Thr Leu Asp Asn Ile Lys Asn Ile Cys His Leu Arg Arg Phe Arg Ser
305 310 315 320
Val Pro Arg Asn Leu Pro Ala Thr Asp Pro Leu Gln Arg Glu Leu Leu
325 330 335
Ala Leu Ile Gln Leu Glu Arg Glu Phe Gln Arg Cys Cys Arg Gln Gly
340 345 350
Asn Asn His Thr Cys Thr Trp Lys Ala Trp Glu Asp Thr Leu Asp Lys
355 360 365
Tyr Cys Asp Arg Glu Tyr Ala Val Lys Thr His His His Leu Cys Cys
370 375 380
Arg His Pro Pro Ser Pro Thr Arg Asp Glu Cys Phe Ala Arg Arg Ala
385 390 395 400
Pro Tyr Pro Asn Tyr Asp Arg Asp Ile Leu Thr Ile Asp Ile Gly Arg
405 410 415
Val Thr Pro Asn Leu Met Gly His Leu Cys Gly Asn Gln Arg Val Leu
420 425 430
Thr Lys His Lys His Ile Pro Gly Leu Ile His Asn Met Thr Ala Arg
435 440 445
Cys Cys Asp Leu Pro Phe Pro Glu Gln Ala Cys Cys Ala Glu Glu Glu
450 455 460
Lys Leu Thr Phe Ile Asn Asp Leu Cys Gly Pro Arg Arg Asn Ile Trp
465 470 475 480
Arg Asp Pro Ala Leu Cys Cys Tyr Leu Ser Pro Gly Asp Glu Gln Val
485 490 495
Asn Cys Phe Asn Ile Asn Tyr Leu Arg Asn Val Ala Leu Val Ser Gly
500 505 510
Asp Thr Glu Asn Ala Lys Gly Gln Gly Glu Gln Gly Ser Thr Gly Gly
515 520 525
Thr Asn Ile Ser Ser Thr Ser Glu Pro Lys Glu Glu
530 535 540
<210> 2
<211> 415
<212> PRT
<213> Human Urine
<400> 2
Met Gly Thr Thr Ala Arg Ala Ala Leu Val Leu Thr Tyr Leu Ala Val
1 5 10 15
Ala Ser Ala Ala Ser Glu Gly Gly Phe Thr Ala Thr Gly Gln Arg Gln
20 25 30
Leu Arg Pro Glu His Phe Gln Glu Val Gly Tyr Ala Ala Pro Pro Ser
35 40 45
Pro Pro Leu Ser Arg Ser Leu Pro Met Asp His Pro Asp Ser Ser Gln
50 55 60
His Gly Pro Pro Phe Glu Gly Gln Ser Gln Val Gln Pro Pro Pro Ser
65 70 75 80
Gln Glu Ala Thr Pro Leu Gln Gln Glu Lys Leu Leu Pro Ala Gln Leu
85 90 95
Pro Ala Glu Lys Glu Val Gly Pro Pro Leu Pro Gln Glu Ala Val Pro
100 105 110
Leu Gln Lys Glu Leu Pro Ser Leu Gln His Pro Asn Glu Gln Lys Glu
115 120 125
Gly Thr Pro Ala Pro Phe Gly Asp Gln Ser His Pro Glu Pro Glu Ser
130 135 140
Trp Asn Ala Ala Gln His Cys Gln Gln Asp Arg Ser Gln Gly Gly Trp
145 150 155 160
Gly His Arg Leu Asp Gly Phe Pro Pro Gly Arg Pro Ser Pro Asp Asn
165 170 175
Leu Asn Gln Ile Cys Leu Pro Asn Arg Gln His Val Val Tyr Gly Pro
180 185 190
Trp Asn Leu Pro Gln Ser Ser Tyr Ser His Leu Thr Arg Gln Gly Glu
195 200 205
Thr Leu Asn Phe Leu Glu Ile Gly Tyr Ser Arg Cys Cys His Cys Arg
210 215 220
Ser His Thr Asn Arg Leu Glu Cys Ala Lys Leu Val Trp Glu Asp Thr
225 230 235 240
Leu Asp Lys Tyr Cys Asp Arg Glu Tyr Ala Val Lys Thr His His His
245 250 255
Leu Cys Cys Arg His Pro Pro Ser Pro Thr Arg Asp Glu Cys Phe Ala
260 265 270
Arg Arg Ala Pro Tyr Pro Asn Tyr Asp Arg Asp Ile Leu Thr Ile Asp
275 280 285
Ile Gly Arg Val Thr Pro Asn Leu Met Gly His Leu Cys Gly Asn Gln
290 295 300
Arg Val Leu Thr Lys His Lys His Ile Pro Gly Leu Ile His Asn Met
305 310 315 320
Thr Ala Arg Cys Cys Asp Leu Pro Phe Pro Glu Gln Ala Cys Cys Ala
325 330 335
Glu Glu Glu Lys Leu Thr Phe Ile Asn Asp Leu Cys Gly Pro Arg Arg
340 345 350
Asn Ile Trp Arg Asp Pro Ala Leu Cys Cys Tyr Leu Ser Pro Gly Asp
355 360 365
Glu Gln Val Asn Cys Phe Asn Ile Asn Tyr Leu Arg Asn Val Ala Leu
370 375 380
Val Ser Gly Asp Thr Glu Asn Ala Lys Gly Gln Gly Glu Gln Gly Ser
385 390 395 400
Thr Gly Gly Thr Asn Ile Ser Ser Thr Ser Glu Pro Lys Glu Glu
405 410 415
<210> 3
<211> 170
<212> PRT
<213> Human Urine
<400> 3
Met Ala Leu Pro Leu Arg Asp Arg Val Lys Glu Ala Thr Pro Leu Gln
1 5 10 15
Gln Glu Lys Leu Leu Pro Ala Gln Leu Pro Ala Glu Lys Glu Val Gly
20 25 30
Pro Pro Leu Pro Gln Glu Ala Val Pro Leu Gln Lys Glu Leu Pro Ser
35 40 45
Leu Gln His Pro Asn Glu Gln Lys Glu Gly Thr Pro Ala Pro Phe Gly
50 55 60
Asp Gln Ser His Pro Glu Pro Glu Ser Trp Asn Ala Ala Gln His Cys
65 70 75 80
Gln Gln Asp Arg Ser Gln Gly Gly Trp Gly His Arg Leu Asp Gly Phe
85 90 95
Pro Pro Gly Arg Pro Ser Pro Asp Asn Leu Asn Gln Ile Cys Leu Pro
100 105 110
Asn Arg Gln His Val Val Tyr Gly Pro Trp Asn Leu Pro Gln Ser Ser
115 120 125
Tyr Ser His Leu Thr Arg Gln Gly Glu Thr Leu Asn Phe Leu Glu Ile
130 135 140
Gly Tyr Ser Arg Cys Cys His Cys Arg Ser His Thr Asn Arg Leu Glu
145 150 155 160
Cys Ala Lys Leu Val Val Arg Leu Gly Ser
165 170
<210> 4
<211> 567
<212> PRT
<213> Human Urine
<400> 4
Met Gly Thr Thr Ala Arg Ala Ala Leu Val Leu Thr Tyr Leu Ala Val
1 5 10 15
Ala Ser Ala Ala Ser Glu Gly Gly Phe Thr Ala Thr Gly Gln Arg Gln
20 25 30
Leu Arg Pro Glu His Phe Gln Glu Val Gly Tyr Ala Ala Pro Pro Ser
35 40 45
Pro Pro Leu Ser Arg Ser Leu Pro Met Asp His Pro Asp Ser Ser Gln
50 55 60
His Gly Pro Pro Phe Glu Gly Gln Ser Gly Lys Glu Gly Arg Gly Pro
65 70 75 80
Arg Pro His Ser Gln Pro Trp Leu Gly Glu Arg Val Gly Cys Ser His
85 90 95
Ile Pro Pro Ser Ile Val Gln Pro Pro Pro Ser Gln Glu Ala Thr Pro
100 105 110
Leu Gln Gln Glu Lys Leu Leu Pro Ala Gln Leu Pro Ala Glu Lys Glu
115 120 125
Val Gly Pro Pro Leu Pro Gln Glu Ala Val Pro Leu Gln Lys Glu Leu
130 135 140
Pro Ser Leu Gln His Pro Asn Glu Gln Lys Glu Gly Thr Pro Ala Pro
145 150 155 160
Phe Gly Asp Gln Ser His Pro Glu Pro Glu Ser Trp Asn Ala Ala Gln
165 170 175
His Cys Gln Gln Asp Arg Ser Gln Gly Gly Trp Gly His Arg Leu Asp
180 185 190
Gly Phe Pro Pro Gly Arg Pro Ser Pro Asp Asn Leu Asn Gln Ile Cys
195 200 205
Leu Pro Asn Arg Gln His Val Val Tyr Gly Pro Trp Asn Leu Pro Gln
210 215 220
Ser Ser Tyr Ser His Leu Thr Arg Gln Gly Glu Thr Leu Asn Phe Leu
225 230 235 240
Glu Ile Gly Tyr Ser Arg Cys Cys His Cys Arg Ser His Thr Asn Arg
245 250 255
Leu Glu Cys Ala Lys Leu Val Trp Glu Glu Ala Met Ser Arg Phe Cys
260 265 270
Glu Ala Glu Phe Ser Val Lys Thr Arg Pro His Trp Cys Cys Thr Arg
275 280 285
Gln Gly Glu Ala Arg Phe Ser Cys Phe Gln Glu Glu Ala Pro Gln Pro
290 295 300
His Tyr Gln Leu Arg Ala Cys Pro Ser His Gln Pro Asp Ile Ser Ser
305 310 315 320
Gly Leu Glu Leu Pro Phe Pro Pro Gly Val Pro Thr Leu Asp Asn Ile
325 330 335
Lys Asn Ile Cys His Leu Arg Arg Phe Arg Ser Val Pro Arg Asn Leu
340 345 350
Pro Ala Thr Asp Pro Leu Gln Arg Glu Leu Leu Ala Leu Ile Gln Leu
355 360 365
Glu Arg Glu Phe Gln Arg Cys Cys Arg Gln Gly Asn Asn His Thr Cys
370 375 380
Thr Trp Lys Ala Trp Glu Asp Thr Leu Asp Lys Tyr Cys Asp Arg Glu
385 390 395 400
Tyr Ala Val Lys Thr His His His Leu Cys Cys Arg His Pro Pro Ser
405 410 415
Pro Thr Arg Asp Glu Cys Phe Ala Arg Arg Ala Pro Tyr Pro Asn Tyr
420 425 430
Asp Arg Asp Ile Leu Thr Ile Asp Ile Gly Arg Val Thr Pro Asn Leu
435 440 445
Met Gly His Leu Cys Gly Asn Gln Arg Val Leu Thr Lys His Lys His
450 455 460
Ile Pro Gly Leu Ile His Asn Met Thr Ala Arg Cys Cys Asp Leu Pro
465 470 475 480
Phe Pro Glu Gln Ala Cys Cys Ala Glu Glu Glu Lys Leu Thr Phe Ile
485 490 495
Asn Asp Leu Cys Gly Pro Arg Arg Asn Ile Trp Arg Asp Pro Ala Leu
500 505 510
Cys Cys Tyr Leu Ser Pro Gly Asp Glu Gln Val Asn Cys Phe Asn Ile
515 520 525
Asn Tyr Leu Arg Asn Val Ala Leu Val Ser Gly Asp Thr Glu Asn Ala
530 535 540
Lys Gly Gln Gly Glu Gln Gly Ser Thr Gly Gly Thr Asn Ile Ser Ser
545 550 555 560
Thr Ser Glu Pro Lys Glu Glu
565

Claims (9)

1. The application of the urine extracellular matrix protein 1 and the polypeptide fragment thereof in preparing SLE diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
2. The use according to claim 1, wherein the amino acid sequence of the urine extracellular matrix protein 1 comprises the amino acid sequence shown in SEQ ID No.1 to 4; or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO 1-4 and has the same function as the amino acid sequence shown in SEQ ID NO 1-4.
3. The use according to claim 1, wherein the formulation is a SLE patient urine extracellular matrix protein 1 and polypeptide fragment detection kit thereof.
4. The use according to claim 3, wherein the kit comprises one or more of an immunization method of an antigen-antibody reaction and a kit thereof such as an aptamer antibody or an antibody fragment capable of specifically binding to extracellular matrix protein 1 and a polypeptide fragment thereof.
5. The use according to claim 3, wherein the detection method comprises a method for directly detecting mass spectra of extracellular matrix protein 1 and polypeptide fragments thereof and the like and a kit related thereto.
6. The use according to claim 3, wherein the detection method comprises a method for directly detecting extracellular matrix protein 1 and polypeptide fragments thereof or related nucleic acid detection and the like and related kits thereof.
7. The use according to claim 3, wherein the kit further comprises a component selected from the group consisting of: solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, secondary antibody diluent, luminous reagent, washing liquid, color developing liquid and stop solution.
8. The use of claim 7, wherein the standard comprises an extracellular matrix protein 1 standard, a humanized tag antibody standard; preferably, the quality control product comprises: extracellular matrix protein 1 control, humanized tag antibody quality control; preferably, the solid support comprises: microparticles, microspheres, slides, test strips, plastic beads, liquid phase chips, microwell plates or affinity membranes, and other carriers of equivalent function.
9. The use according to claim 8, wherein the solid support is made of any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose and a support with similar function.
CN202210241035.9A 2022-03-13 2022-03-13 Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus Pending CN117233396A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210241035.9A CN117233396A (en) 2022-03-13 2022-03-13 Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210241035.9A CN117233396A (en) 2022-03-13 2022-03-13 Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CN117233396A true CN117233396A (en) 2023-12-15

Family

ID=89091656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210241035.9A Pending CN117233396A (en) 2022-03-13 2022-03-13 Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus

Country Status (1)

Country Link
CN (1) CN117233396A (en)

Similar Documents

Publication Publication Date Title
CN117233396A (en) Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus
CN113777314A (en) Application of urine ankle protein 1 and polypeptide fragment thereof in burn
CN117147860A (en) Application of urine heparin cofactor II and polypeptide fragment thereof in systemic lupus erythematosus
CN117147842A (en) Application of urine coagulation factor IX and polypeptide fragment thereof in systemic lupus erythematosus
CN117147863A (en) Application of urine serine protease inhibitor and polypeptide fragment thereof in systemic lupus erythematosus
CN116794315A (en) Application of urine alpha-trypsin inhibitor heavy chain H4 and polypeptide fragment thereof in systemic lupus erythematosus
CN117147861A (en) Application of urine alpha-trypsin inhibitor heavy chain H2 and polypeptide fragment thereof in systemic lupus erythematosus
CN117147862A (en) Application of urine alpha-trypsin inhibitor heavy chain H3 and polypeptide fragment thereof in systemic lupus erythematosus
CN117147841A (en) Application of urokinase plasminogen activator and polypeptide fragment thereof in systemic lupus erythematosus
CN117147847A (en) Application of urine immunoglobulin kappa light chain and polypeptide fragment thereof in systemic lupus erythematosus
CN115201482A (en) Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus
CN114113640A (en) Application of urine blood coagulation factor IX and polypeptide fragment thereof in burn
CN117147852A (en) Application of urine keratin I-type cytoskeleton 18 and polypeptide fragment thereof in allergic diseases
CN117147856A (en) Application of urine interleukin 4 receptor A and polypeptide fragment thereof in allergic diseases
CN113777315A (en) Application of uroubiquitin-like protein ISG15 and polypeptide fragment thereof in burn
CN114252603A (en) Urine catalase and application of polypeptide fragment thereof in allergic diseases
CN113777313A (en) Application of urine vitamin K-dependent protein S and polypeptide fragment thereof in burn
CN113820485A (en) Urine carbonic anhydrase 3 and application of polypeptide fragment thereof in burn
CN114252620A (en) Application of urine neutrophil gelatinase-associated lipocalin and polypeptide fragment thereof in allergic diseases
CN114252605A (en) Application of urine myeloperoxidase and polypeptide fragment thereof in allergic diseases
CN113777302A (en) Application of urine complement factor D and polypeptide fragment thereof in burn
CN113804894A (en) Application of urine tumor necrosis factor receptor superfamily member 19L and polypeptide fragment thereof in burn
CN113777304A (en) Application of urine plasminogen and polypeptide fragment thereof in burn
CN114252628A (en) Application of urine regeneration protein and polypeptide fragment thereof in allergic diseases
CN113777305A (en) Application of urine monoadenosine diphosphate ribosyltransferase and polypeptide fragment thereof in burn

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication